Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a global health issue, worsened by aging and type 2 diabetes, with cardiovascular complications posing a significant burden.
• Current dyslipidemia treatments in CKD focus on LDL cholesterol but leave residual cardiovascular risk.
• Elevated triglycerides and low HDL cholesterol are common in CKD, suggesting these as therapeutic targets.

Purpose of the Study:

• To review the novel therapeutic approach of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) for managing dyslipidemia in CKD.
• To differentiate the safety and efficacy profile of pemafibrate, a SPPARMα, from traditional fibrates in CKD patients.
• To assess the potential of pemafibrate in addressing unmet clinical needs and reducing residual cardiovascular risk in CKD.

Main Methods:

• Review of preclinical and clinical evidence on SPPARMα agents, focusing on pemafibrate.
• Comparative analysis of pemafibrate's effects on lipid profiles and renal function versus traditional fibrates.
• Discussion of ongoing clinical trials, such as the PROMINENT study, evaluating pemafibrate's long-term outcomes.

Main Results:

• Pemafibrate, as a SPPARMα, is designed for enhanced selectivity and safety at the PPARα receptor.
• Evidence suggests pemafibrate does not elevate serum creatinine or worsen renal function in high-risk patients, including those with CKD.
• Pemafibrate demonstrates a favorable lipid-modifying profile, targeting triglycerides and HDL cholesterol.

Conclusions:

• Pemafibrate represents a potential advancement in treating dyslipidemia in CKD, offering an improved safety profile compared to current fibrates.
• Further data from studies like PROMINENT are crucial to confirm pemafibrate's efficacy in reducing cardiovascular events in diabetic patients with CKD.
• Targeting residual cardiovascular risk through novel agents like pemafibrate is essential for improving outcomes in CKD management.